Tiroid Oftalmopati ve Şaşılık

Bahn RS, Heufelder AE. Pathogenesis of Graves’ ophthalmopathy. N Engl J Med. 1993;329:1468–75.

Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010 Feb 25; 362(8): 726–738.

Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid. 2002;12:855–60.

Gerding MN, van der Meer JW, Broenink M, et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin Endocrinol (Oxf) 2000;52:267–71.

Prummel MF, Wiersinga WM. Smoking and risk of Graves’ disease. JAMA. 1993;269:479–82.

Yurdakul NS. Tiroid Oftalmopati: Şaşılık. TOD Yayınları No 7. 2008;139-148.

Şahlı E, Gündüz K. Tiroid Oftalmopati. Turk J Ophthalmol 2017;47:94-105.

McGregor AM. Has the target autoantigen for Graves’ ophthalmopathy been found? Lancet. 1998;352:595-596

Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91:3464–70.

Kumar S, Schiefer R, Coenen MJ, et al. A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves’ orbital preadipocyte fibroblasts. Thyroid. 2010;20:59-65.

Heufelder AE. Pathogenesis of Graves’ ophthalmopathy: recent controversies and progress. Eur J Endocrinol. 1995;132:532-541.

Aniszewski JP, Valyasevi RW, Bahn RS. Relationship between disease duration and predominant orbital T cell subset in Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2000;85:776–80.

Wang Y, Smith TJ. Current concepts in the molecular pathogenesis of thyroid associated ophthalmopathy. Invest Ophthalmol Vis Sci. 2014;55:1735-1748.

Werner SC. Classification of the eye changes of Graves’ disease. J Clin Endocrinol Metab. 1969;29:982-984.

Wiersinga WM, Smit T, van der Gaag R, et al. Clinical presentation of Graves’ ophthalmopathy. Ophthalmic Res. 1989;21:73–82.

Ross DS, Burch HB, Cooper DS, et al. 2016. American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016 October 01;26(10):1343–1421.

Jhonson BT, Jameyfield E, Aakalu VK. Optic Neuropathy and Diplopia from Thyroid Eye Disease: Update on Pathophysiology and Treatment. 2021 Feb 1;34(1):116-121.

Skov CM, Mazow ML. Managing strabismus in endocrine eye disease. Can J Ophthalmol. 1984;19:269–74.

Dyer JA. The oculorotary muscles in Graves'disease. Trans Am Ophthalmol Soc. 1976;74:425–56.

Akbari MR, Mirmohammadsadeghi A, Mahmoudzadeh R, et al. Management of Thyroid Eye Disease-Related Strabismus. J Curr Ophthalmol. 2020 Jan-Mar; 32(1): 1–13.

Lo C, Ugradar S, Rootman D. Management of graves myopathy:Orbital imaging in thyroid-related orbitopathy. J AAPOS. 2018;22:256.

Khoo DH, Eng PH, Ho SC, et al. Graves’ ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels. Thyroid. 2000;10:1093–1100.

Stan MN, Garrity JA, Bahn RS. The evaluation and treatment of Graves ophthalmopathy. Med Clin North Am. 2012;96:311-328.

Kahaly GJ. Management of moderately severe Graves’ orbitopathy. In: Wiersinga WM, Kahaly GJ, eds. Graves orbitopathy: A multidisciplinary approach. Basel; Karger; 2007:120-152.

Aktaran S, Akarsu E, Erbağci I, et al. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves’ ophthalmopathy. Int J Clin Pract. 2007;61:45-51.

Stan MN, Garrity JA, Bahn RS. The evaluation and treatment of Graves ophthalmopathy. Med Clin North Am. 2012;96:311-328.

Mourits MP, Koornneef L, van Mourik-Noordenbos AM, et al. Extraocular muscle surgery for Graves’ ophthalmopathy: does prior treatment influence surgical outcome? Br J Ophthalmol. 1990;74:481-483.

Sanaç AŞ, Şener EC. Şaşılık ve Tedavisi. Restriktif Şaşılıklar: Şaşılık ve Tedavisi. 2. Baskı. 2001:159-180.